Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Glenmark Debuts Favipiravir For COVID-19 In India

Poised For Scale-Up Using In-House Capabilities

Jun 22 2020

• By Anju Ghangurde

Coronavirus COVID-19 medical test vaccine research and development concept. Scientist in laboratory study and analyze scientific sample of Coronavirus antibody to produce drug treatment for COVID-19. — Favipiravir Gets India Green Light After Accelerated Approval • Source: Shutterstock

Related Content

Gilead Licenses Remdesivir To Five Firms

May 13 2020

Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral

Jun 01 2020

India Remdesivir Supplies: 'Peculiar' Situation, Flip Flops And Bangladesh Touch

Jun 11 2020

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

May 27 2020

Gilead Licensing Deal Expands Remdesivir Access, Capacity

May 13 2020

Coronavirus Update: AZ Gets $1bn From US, Secures Capacity For One Billion Vaccine Doses

May 21 2020

Strides Optimistic On Prospects Of Antiviral Portfolio For COVID-19

May 22 2020

Related Companies

Glenmark Pharmaceuticals Limited

FUJIFILM Holdings Corp.

Cipla Limited

Strides Pharma Science Limited

Gilead Sciences, Inc.

Hetero Drugs Ltd.

Additional Topics

India Asia Pacific Coronavirus COVID-19 Generic Drugs Strategy BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window